피티씨 테라퓨틱스(PTCT) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 피티씨 테라퓨틱스(PTCT)?

피티씨 테라퓨틱스(PTCT) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of PTCT?

The market cap of PTCT is approximately $6.3B, ranking 1,234 within its sector.

Q: What is the 52-week high and low for PTCT?

PTCT has recorded a 52-week high of $90.87 and a low of $43.17.

PTCT

PTC Therapeutics Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$75.80

-1.02 ▼ -1.33%

🌙 7월 27일 6:32 PM ET (한국 7/28 07:32)

$74.66

-1.14 ▼ -1.50%

피티씨 테라퓨틱스(PTCT) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$6.3B

스몰캡

P/E

배당수익률

없음

52주 위치

68%

저점 +76% · 고점 -17%

애널리스트

매수

Fundamental health

vs. 초고성장주 중형주· based on 3 axes

수익성

산출 불가 (적자)

성장

Top 68%

밸류에이션

Top 61%

재무 안정

Top 45%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 1년 (not other companies).

Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 8원. Over the past 1년, it usually traded around 7원. On the pricier side versus its own history.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 1 profitable years

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-2.34	Insider Own ⓘ	3.4%	Shs Outstand ⓘ	82.9M	Perf Week ⓘ	-2.83%
Market Cap ⓘ	6.29B	Forward P/E ⓘ	29.41	EPS next Y ⓘ	343.92%	Insider Trans ⓘ	-10.44%	Shs Float ⓘ	80.1M	Perf Month ⓘ	-10.31%
Enterprise Value ⓘ	4.79B	PEG ⓘ	-	EPS next Q ⓘ	0.24	Inst Own ⓘ	115.62%	Short Float ⓘ	12.27%	Perf Quarter ⓘ	11.09%
Income ⓘ	-0.19B	P/S ⓘ	7.6	EPS this Y ⓘ	-92.54%	Inst Trans ⓘ	2.92%	Short Ratio ⓘ	5.37	Perf Half Y ⓘ	0.73%
Sales ⓘ	0.83B	P/B ⓘ	-	EPS next 5Y ⓘ	-16.13%	ROA ⓘ	-6.76%	Short Interest ⓘ	9.83M	Perf YTD ⓘ	-0.21%
Book/sh ⓘ	-2.18	P/C ⓘ	3.32	EPS past 3/5Y ⓘ	-	ROE ⓘ	-	52W High ⓘ	-16.58% ($90.87)	Perf Year ⓘ	69.42%
Cash/sh ⓘ	22.81	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	35.3% 35.37%	ROIC ⓘ	-	52W Low ⓘ	75.56% ($43.17)	Perf 3Y ⓘ	95.66%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-130.87%	Gross Margin ⓘ	88.55%	Volatility(W/M) ⓘ	3.29% 3.96%	Perf 5Y ⓘ	94.21%
Dividend TTM ⓘ	-	EV/Sales ⓘ	5.79	Sales Y/Y TTM ⓘ	-53.34%	Oper. Margin ⓘ	-8.11%	ATR (14) ⓘ	3.16	Perf 10Y ⓘ	1227.5%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	2.36	EPS Q/Q ⓘ	-100.34%	Profit Margin ⓘ	-22.58%	RSI (14) ⓘ	40	Recom ⓘ	1.87
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	2.44	Sales Q/Q ⓘ	-76.83%	SMA20 ⓘ	-6.81% ($81.34)	Beta ⓘ	0.56	Target Price ⓘ	$96.07
Payout ⓘ	-	Debt/Eq ⓘ	-	Earnings ⓘ	2026/7/30	SMA50 ⓘ	-1.51% ($76.96)	Rel Volume ⓘ	0.99	Prev Close ⓘ	$76.82
Employees ⓘ	991	LT Debt/Eq ⓘ	-	EPS/Sales Surpr. ⓘ	93.64% 25.36%	SMA200 ⓘ	3.89% ($72.96)	Avg Volume(3M) ⓘ	1.83M	Price ⓘ	$75.8
IPO ⓘ	2013/6/20	Option/Short ⓘ	Yes/Yes			Trades ⓘ	17202	Volume ⓘ	1,811,427	Change ⓘ	-1.33%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $273M (YoY -77%) · 순이익 $-3M (YoY -100%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 PTC Therapeutics Inc (PTCT) Investment Analysis

What kind of company is PTC Therapeutics Inc?

피티씨 테라퓨틱스(PTCT) 초고성장주

Healthcare · Biotechnology

#1234 by Market Cap — Mid-Cap

🧬 This is a commercial-stage biotech company that develops and markets treatments for rare diseases. It sells therapies for conditions such as muscular dystrophy and metabolic disorders, earns royalty revenue through partnerships, and maintains a diverse pipeline. As a healthcare stock, its earnings and valuation are closely tied to sales of its key therapies, royalty income, and progress in clinical development.

Learn more about PTC Therapeutics Inc →

Market Cap

$6.3B

Approx. KRW 8.6 trillion

⚖️ 2% of Samsung Electronics

Market Cap Rank1234

Employees991people

IPO2013/06/20

Current Price$75.80 ≈ 103,846원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-3

7월 30일 (목) · 장 마감 후

예상 EPS $0.24

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후 EPS +93.6% 매출 +25.4%

🔔 Earnings release 2026년 2월 19일 (목) · 장 마감 후 EPS -1718.2% 매출 -41.1%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-8.1%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-22.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

88.5%

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology 중형주 Median 82.6% · Top 29%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROA

Annual earnings relative to total company assets

-6.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Current Ratio

Liquid assets available to cover liabilities due within a year

2.44

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

2.36

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$96.07

현재가 대비 +26.7%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

29.41배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+343.9%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

-16.1%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

-502.1%

평균 서프라이즈

2026.05.07

상회

실적 $-0.03 · 예상 $-0.44 +93.2%

2026.02.19

하회

실적 $-1.80 · 예상 $-0.15 -1097.5%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow

Historical growth is expected to lose momentum

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-92.5%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 중형주 Median 49.3% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+343.9%

우수

My positionTop 5%

Low range Average High range

초고성장주 중형주 Median 31.3% · Top tier

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

-16.1%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 중형주 Median 39.1% · Bottom tier

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+35.4%

양호

My positionMid-range

Low range Average High range

초고성장주 중형주 Median 30.4% · Top 40%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-76.8%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 중형주 Median 18.9% · Bottom tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Slightly outperformed the market over 5 years (+26%p)

PTCT +94.2% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

+25.9%p

ahead of the market

vs Health Care (XLV)

+69.7%p

well ahead of the sector average

1-year basis

vs S&P 500

+53.4%p

well ahead of the market

vs Health Care (XLV)

+49.7%p

well ahead of the sector average

Rank among peers

5-year return Upper-Mid (43%) Based on 64 peers

1-year return Lower-Mid (lower 40%) Based on 76 peers

Current position within 52-week range

Low (-75.6%p) High (-16.6%p)

Current price is 75.6% above the 52-week low and 16.6% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-15.9%

Annualized volatility

44.4%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $75.80 below the midline ($81.34). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.395 < Signal 0.660 in negative zone + Hist negative (-1.055). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 40.0 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 0.5.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Sales, In line with peers on Vs. Earnings

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Mid-range

🧾 Vs. Sales Cheap

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

29.41x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 중형주 median 27.75x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

7.60x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 중형주 median 23.18x · Top 24% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$96.07 vs. current price +26.7%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 중형주

Who owns it?

Ownership flow shows some pressure

Insider net selling -10.4% · Institutional net buying +2.9% · Short interest elevated 12.3%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-10.4%

Insiders large net selling

🏦 Institutions (funds & investors)

+2.9%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 115.6%

Institution-led, stable structure

Healthcare 중형주 Median 89.4%

🧑‍💼 Insiders 3.4%

Typical level

Healthcare 중형주 Median 9.4%

👤 Retail investors (estimated) 0.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

12.3%

Somewhat high

Healthcare 중형주 Median 11.3%

Past 90 days Little change

Short interest days to cover

5.4 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 82.9M주

Float (tradable shares) 80.1M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding PTCT

ETFs with the highest weightings · 10 total shown

IBRN

iShares Neuroscience and Healthcare ETF

3.69%

$6M

PSCH

Invesco S&P SmallCap Health Care ETF

3.26%

$162M

PBE

Invesco Biotechnology & Genome ETF

2.68%

$281M

FCUS

Pinnacle Focused Opportunities ETF

2.13%

$82M

HELX

Franklin Genomic Advancements ETF

1.48%

$29M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
PTCT This Stock	$6.3B	-	-	-	-	-1.3%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 피티씨 테라퓨틱스(PTCT)?

피티씨 테라퓨틱스(PTCT) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of PTCT?

The market cap of PTCT is approximately $6.3B, ranking 1,234 within its sector.

What is the 52-week high and low for PTCT?

PTCT has recorded a 52-week high of $90.87 and a low of $43.17.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.